OMN6

Phase 2Small molecule

OOmnix Medical Ltd

OMN6 is one of 9 small molecule programs targeting Bacterial Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial PneumoniaRecruiting

Bacterial PneumoniaPhase 2

Recruiting

Competition

Competitive Landscape

10 competitors in Bacterial Pneumonia

#DrugCompanyPhaseTrials

Biaxin

Ketek

Levaquin

2 4

Avycaz

PPhiladelphia Eye Associates

Approved

—5

Tygacil

PPrism Pharmaceuticals

Amikin

Teflaro

3 8

Polymyxin B

MMahidol University

Phase 3

1 9

OMN6

OOmnix Medical Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Bacterial Pneumonia

NCT06087536

Clinical

Trials by Indication[1]

Bacterial Pneumonia1 trial

A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).

Recruiting·OOmnix Medical Ltd·Phase 2·NCT06087536·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OMN6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OMN6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OMN6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Omnix Medical Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOmnix Medical Ltd

OMN6

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Bacterial Pneumonia1 trial

References

Drug Info

Quick Facts

Related News